[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 44 of about 44
1. Gilani N, Gerkin RD, Ramirez FC, Hakim S, Randolph AC: Prevalence of Barrett's esophagus in patients with moderate to severe erosive esophagitis. World J Gastroenterol; 2008 Jun 14;14(22):3518-22
Genetic Alliance. consumer health - Barrett's Esophagus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of Barrett's esophagus in patients with moderate to severe erosive esophagitis.
  • AIM: To investigate the proportion of patients with moderate-severe erosive esophagitis (EE) who will have Barrett's esophagus (BE) after healing of inflammation.
  • Even when suspected, BE and associated dysplasia can be missed in the presence of inflammation; therefore, repeat evaluation should be considered after complete healing of esophagitis.
  • [MeSH-major] Barrett Esophagus / epidemiology. Barrett Esophagus / etiology. Esophagitis / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2002 Aug;123(2):461-7 [12145799.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):516-24 [17970839.001]
  • [Cites] Am J Gastroenterol. 2004 Apr;99(4):582-8 [15089886.001]
  • [Cites] Gastroenterology. 1977 Apr;72(4 Pt 1):669-75 [838221.001]
  • [Cites] Semin Gastrointest Dis. 1996 Apr;7(2):51-60 [8705259.001]
  • [Cites] Am J Gastroenterol. 1999 Apr;94(4):937-43 [10201460.001]
  • [Cites] Am J Gastroenterol. 1999 Jun;94(6):1434-42 [10364004.001]
  • [Cites] Gastrointest Endosc. 2005 Feb;61(2):226-31 [15729230.001]
  • [Cites] Gut. 2005 May;54(5):710-7 [15831922.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Mar 1;23(5):595-9 [16480398.001]
  • [Cites] Am J Gastroenterol. 2006 Jun;101(6):1193-9 [16771936.001]
  • [Cites] Am J Gastroenterol. 2006 Jul;101(7):1416-20 [16863541.001]
  • [Cites] Am J Gastroenterol. 2006 Oct;101(10):2187-93 [17032182.001]
  • [Cites] World J Gastroenterol. 2007 Mar 14;13(10):1585-94 [17461453.001]
  • [Cites] Gastroenterol Clin Biol. 2007 Jun-Jul;31(6-7):601-6 [17646787.001]
  • [Cites] World J Gastroenterol. 2007 Dec 7;13(45):6009-15 [18023091.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1670-7 [14724819.001]
  • (PMID = 18567080.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2716614
  •  go-up   go-down


2. Lovat LB, Johnson K, Mackenzie GD, Clark BR, Novelli MR, Davies S, O'Donovan M, Selvasekar C, Thorpe SM, Pickard D, Fitzgerald R, Fearn T, Bigio I, Bown SG: Elastic scattering spectroscopy accurately detects high grade dysplasia and cancer in Barrett's oesophagus. Gut; 2006 Aug;55(8):1078-83
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elastic scattering spectroscopy accurately detects high grade dysplasia and cancer in Barrett's oesophagus.
  • BACKGROUND AND AIMS: Endoscopic surveillance of Barrett's oesophagus currently relies on multiple random biopsies.
  • The aim of this study was to assess the potential for elastic scattering to detect high grade dysplasia or cancer within Barrett's oesophagus.
  • METHODS: Elastic scattering spectroscopy measurements collected in vivo were matched with histological specimens taken from identical sites within Barrett's oesophagus.
  • All biopsies were reviewed by three gastrointestinal pathologists and defined as either "low risk" (non-dysplastic or low grade dysplasia) or "high risk" (high grade dysplasia or cancer).
  • There was good pathologist agreement in differentiating high grade dysplasia and cancer from other pathology (kappa = 0.72).
  • A negative spectroscopy result would exclude high grade dysplasia or cancer with an accuracy of >99.5%.
  • CONCLUSIONS: These preliminary results show that elastic scattering spectroscopy has the potential to target conventional biopsies in Barrett's surveillance saving significant endoscopist and pathologist time with consequent financial savings.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 1997 Apr;92(4):586-91 [9128304.001]
  • [Cites] Gastroenterology. 1996 Jul;111(1):93-101 [8698231.001]
  • [Cites] Cancer. 1998 Dec 25;84(6):366-74 [9915139.001]
  • [Cites] Hum Pathol. 1988 Feb;19(2):166-78 [3343032.001]
  • [Cites] Gastroenterology. 1990 Jul;99(1):150-7 [2160898.001]
  • [Cites] Gut. 1998 Aug;43(2):216-22 [10189847.001]
  • [Cites] Dig Dis. 2004;22(2):134-41 [15383754.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2004 Jul;14(3):507-17, ix [15261199.001]
  • [Cites] Oral Oncol. 2004 Aug;40(7):673-8 [15172636.001]
  • [Cites] J Pathol. 2003 Aug;200(5):602-9 [12898596.001]
  • [Cites] J Clin Pathol. 2002 Dec;55(12):910-6 [12461055.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):1888-95 [12190150.001]
  • [Cites] Ann Thorac Surg. 2002 Jun;73(6):1697-702; discussion 1702-3 [12078755.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):588-90 [11845805.001]
  • [Cites] Am J Gastroenterol. 2001 Oct;96(10):2839-48 [11693316.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1620-9 [11375944.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1607-19 [11375943.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):379-88 [11331954.001]
  • [Cites] Am J Gastroenterol. 2000 Dec;95(12):3383-7 [11151865.001]
  • [Cites] Am J Gastroenterol. 2000 Nov;95(11):3089-96 [11095322.001]
  • [Cites] BMJ. 2000 Nov 18;321(7271):1252-5 [11082084.001]
  • [Cites] Gastroenterology. 2000 Sep;119(3):677-82 [10982761.001]
  • [Cites] J Biomed Opt. 2000 Apr;5(2):221-8 [10938787.001]
  • [Cites] J Biomed Opt. 2000 Apr;5(2):131-7 [10938776.001]
  • [Cites] Am J Gastroenterol. 2000 Jul;95(7):1669-76 [10925966.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] Nature. 2000 Jul 6;406(6791):35-6 [10894529.001]
  • [Cites] Gastrointest Endosc. 2006 Feb;63(2):257-61 [16427931.001]
  • [Cites] Arch Oral Biol. 2005 Mar;50(3):361-6 [15740716.001]
  • [Cites] J Biomed Opt. 2004 Nov-Dec;9(6):1122-8 [15568931.001]
  • [Cites] Gastroenterology. 1992 Apr;102(4 Pt 1):1212-9 [1551528.001]
  • [Cites] Lasers Surg Med. 1995;17(4):350-7 [8684237.001]
  • [Cites] Br J Surg. 1997 Oct;84(10):1470-3 [9361616.001]
  • (PMID = 16469795.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U54-CA104677-02
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1856278
  •  go-up   go-down


3. Hoara P, Gindea C, Birla R, Mocanu A, Tavlas E, Constantinoiu S: The treatment of Barrett's esophagus. J Med Life; 2009 Jul-Sep;2(3):241-8
Genetic Alliance. consumer health - Barrett's Esophagus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The treatment of Barrett's esophagus.
  • When the healing of the lesion is done by replacing the normal squamous epithelium with columnar epithelium, the entity is called Barrett's esophagus (BE).
  • Taking into consideration the possible development of an adenocarcinoma, the patients with Barrett's esophagus require endoscopic surveillance after a standardized protocol.
  • There is still much controversy about the treatment of patients with Barrett's esophagus, especially in the presence of dysplasia.
  • The aims of the treatment are gastro-esophageal reflux symptoms control, healing of associated esophagitis and prevention of development of adenocarcinoma.
  • [MeSH-major] Barrett Esophagus / therapy
  • [MeSH-minor] Adenocarcinoma / etiology. Adenocarcinoma / prevention & control. Esophageal Neoplasms / etiology. Esophageal Neoplasms / prevention & control. Esophagectomy. Esophagitis / complications. Esophagitis / therapy. Esophagoscopy. Gastroesophageal Reflux / complications. Gastroesophageal Reflux / therapy. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20112466.001).
  • [ISSN] 1844-122X
  • [Journal-full-title] Journal of medicine and life
  • [ISO-abbreviation] J Med Life
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Romania
  • [Number-of-references] 36
  •  go-up   go-down


Advertisement
4. Tantau M, Mosteanu O, Pop T, Tantau A, Mester G: Endoscopic therapy of Barrett's esophagus and esophageal adenocarcinoma. J Gastrointestin Liver Dis; 2010 Jun;19(2):213-7
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic therapy of Barrett's esophagus and esophageal adenocarcinoma.
  • Esophagitis will progress to Barrett metaplasia in 10% of patients who would be of minor clinical interest if it then did not advance to low, high grade dysplasia and invasive carcinoma.
  • A multimodal approach of Barrett's esophagus with high grade dysplasia is required, including endoscopic mucosal resection, photodynamic therapy and thermal ablation.
  • Photodynamic therapy could be used for the management of patients with high grade dysplasia, early EAC, local recurrence post radical therapy, microscopic involvement of tumor borders post radical resection, patient unfit / unwilling to undergo surgery.
  • [MeSH-major] Adenocarcinoma / therapy. Barrett Esophagus / therapy. Esophageal Neoplasms / therapy. Esophagoscopy

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20593060.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Romania
  •  go-up   go-down


5. Foroulis CN, Thorpe JA: Photodynamic therapy (PDT) in Barrett's esophagus with dysplasia or early cancer. Eur J Cardiothorac Surg; 2006 Jan;29(1):30-4
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy (PDT) in Barrett's esophagus with dysplasia or early cancer.
  • OBJECTIVE: Esophagectomy is the standard treatment for high-grade dysplasia (HGD) and intramucosal adenocarcinoma (IMC) arising within Barrett's esophagus.
  • Results of photodynamic therapy (PDT) were retrospectively studied to evaluate the effectiveness of PDT in ablating HGD and/or IMC complicating Barrett's esophagus.
  • The mean Barrett's length was 5.8+/-2.2 cm.
  • Pre-PDT endoscopic mucosal resection or Nd:YAG laser ablation of mucosal nodularity within Barrett's segment was offered in six patients.
  • RESULTS: The main PDT complications were esophagitis (16.1%), photoreactions (12.9%) and stricture requiring dilatation (6.25%).
  • CONCLUSIONS: PDT is effective in ablating HGD/IMC complicating Barrett's esophagus in the majority of cases, while it also seems to be quite effective in treating T1b/limited T2 carcinomas.
  • [MeSH-major] Adenocarcinoma / drug therapy. Barrett Esophagus / drug therapy. Esophageal Neoplasms / drug therapy. Photochemotherapy / methods

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16337389.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Photosensitizing Agents; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


6. Kuester D, Dar AA, Moskaluk CC, Krueger S, Meyer F, Hartig R, Stolte M, Malfertheiner P, Lippert H, Roessner A, El-Rifai W, Schneider-Stock R: Early involvement of death-associated protein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association with clinical progression. Neoplasia; 2007 Mar;9(3):236-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early involvement of death-associated protein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association with clinical progression.
  • Esophageal Barrett's adenocarcinoma (BA) develops through a multistage process, which is associated with the transcriptional silencing of tumor-suppressor genes by promoter CpG island hypermethylation.
  • In this study, we explored the promoter hypermethylation and protein expression of proapoptotic death-associated protein kinase (DAPK) during the multistep Barrett's carcinogenesis cascade.
  • Hypermethylation of DAPK promoter was detected in 20% of normal mucosa, 50% of Barrett's metaplasia, 53% of dysplasia, and 60% of adenocarcinomas, and resulted in a marked decrease in DAPK protein expression (P < .01).
  • Moreover, the severity of reflux esophagitis correlated significantly with the hypermethylation rate of the DAPK promoter (P < .003).
  • Thus, we consider DAPK inactivation by promoter hypermethylation as an early event in Barrett's carcinogenesis and suggest that a decreased protein expression of DAPK likely plays a role in the development and progression of BA.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Cell Biol. 2001 Jan;3(1):1-7 [11146619.001]
  • [Cites] Cancer Lett. 2006 Aug 18;240(1):69-75 [16246486.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2847-51 [11306456.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3225-9 [11309270.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3410-8 [11309301.001]
  • [Cites] Oncogene. 2001 Mar 29;20(14):1765-70 [11313923.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):590-1 [11845806.001]
  • [Cites] Gastroenterology. 2002 Apr;122(4):1113-21 [11910361.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2912-9 [12912936.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1511-6 [10995806.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5021-6 [11016622.001]
  • [Cites] Lancet. 2000 Dec 16;356(9247):2079-85 [11145505.001]
  • [Cites] Virchows Arch. 2004 Aug;445(2):135-41 [15185075.001]
  • [Cites] Dig Dis. 2004;22(2):126-33 [15383753.001]
  • [Cites] Dig Dis. 2004;22(2):196-201 [15383761.001]
  • [Cites] Cancer Sci. 2004 Sep;95(9):736-40 [15471559.001]
  • [Cites] Genes Dev. 1995 Jan 1;9(1):15-30 [7828849.001]
  • [Cites] EMBO J. 1997 Mar 3;16(5):998-1008 [9118961.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Nature. 1997 Nov 13;390(6656):180-4 [9367156.001]
  • [Cites] EMBO J. 1998 Apr 15;17(8):2426-35 [9545253.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] Gastroenterology. 1998 Dec;115(6):1381-6 [9834265.001]
  • [Cites] Am J Pathol. 1999 Apr;154(4):965-73 [10233832.001]
  • [Cites] Gastroenterology. 1999 Jul;117(1):218-28 [10381931.001]
  • [Cites] J Cell Biol. 1999 Jul 12;146(1):141-8 [10402466.001]
  • [Cites] Int J Oncol. 2005 Jun;26(6):1493-500 [15870861.001]
  • [Cites] Oncogene. 2005 Jun 9;24(25):4138-48 [15824739.001]
  • [Cites] Neoplasia. 2005 Apr;7(4):331-5 [15967110.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Sep;37(9):1763-7 [16009322.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6544-9 [16166431.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2113-7 [16172218.001]
  • [Cites] Neoplasia. 2005 Sep;7(9):854-61 [16229808.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Nov;131(11):733-40 [16075282.001]
  • [Cites] J Pathol. 2006 May;209(1):95-105 [16575786.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):939-42 [11221887.001]
  • (PMID = 17401463.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA106176; United States / NCI NIH HHS / CA / CA106176
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; EC 2.7.11.1 / Death-Associated Protein Kinases; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases
  • [Other-IDs] NLM/ PMC1838580
  •  go-up   go-down


7. Hritz I, Gyorffy H, Molnar B, Lakatos G, Sipos F, Pregun I, Juhasz M, Pronai L, Schaff Z, Tulassay Z, Herszenyi L: Increased p53 expression in the malignant transformation of Barrett's esophagus is accompanied by an upward shift of the proliferative compartment. Pathol Oncol Res; 2009 Jun;15(2):183-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased p53 expression in the malignant transformation of Barrett's esophagus is accompanied by an upward shift of the proliferative compartment.
  • Neoplastic progression in Barrett's esophagus (BE) occurs by a multistep process associated with early molecular and morphological changes.
  • PCNA and p53 expressions were analyzed in biopsy samples by immunohistochemistry including patients with reflux esophagitis, BE, BE with concomitant esophagitis, Barrett's dysplasia, esophageal adenocarcinoma and a control group without any histological changes.
  • While cell proliferation was significantly lower in the control group compared with all other groups, there was no increase in p53 expression of esophageal tissues that were negative for dysplasia.
  • Dysplastic BE tissues revealed significantly higher cell proliferation and p53 expression levels compared to BE, reflux esophagitis or BE with concomitant esophagitis.
  • Both, cell proliferation and p53 expression were significantly higher in adenocarcinoma compared to BE or Barrett's dysplasia.
  • Interestingly, while just BE with concomitant esophagitis showed significantly higher p53 expression levels than BE, both, BE with concomitant esophagitis and reflux esophagitis revealed significantly higher cell proliferation levels compared to BE.
  • [MeSH-major] Adenocarcinoma / metabolism. Barrett Esophagus / metabolism. Biomarkers, Tumor / metabolism. Cell Transformation, Neoplastic / metabolism. Esophageal Neoplasms / metabolism. Proliferating Cell Nuclear Antigen / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Proliferation. Esophagitis, Peptic / metabolism. Esophagitis, Peptic / pathology. Female. Humans. Immunoenzyme Techniques. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18752044.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


8. Anagnostopoulos GK, Yao K, Kaye P, Hawkey CJ, Ragunath K: Novel endoscopic observation in Barrett's oesophagus using high resolution magnification endoscopy and narrow band imaging. Aliment Pharmacol Ther; 2007 Aug 1;26(3):501-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel endoscopic observation in Barrett's oesophagus using high resolution magnification endoscopy and narrow band imaging.
  • BACKGROUND: High resolution magnification endoscopy with narrow band imaging (NBI) may improve the detection of specialised intestinal metaplasia (SIM) and dysplasia in Barrett's oesophagus.
  • AIMS: To describe the magnified endoscopic features with the use of NBI in Barrett's oesophagus.
  • METHODS: Three hundred and forty-four areas from 50 patients with Barrett's oesophagus were studied using high resolution magnification endoscopy (HRME) with NBI and targeted biopsies were obtained.
  • The sensitivity, specificity, predictive values of the various patterns for the prediction of SIM and dysplasia were calculated.
  • RESULTS: The magnified endoscopic features of Barrett's oesophagus with the use of NBI consist of microstructural/microvascular patterns.
  • The sensitivity, specificity, positive and negative predictive values of the irregular microvascular/microstructural pattern for the prediction of high grade dysplasia were 90%, 100%, 99.2% and 100%, respectively.
  • CONCLUSION: High resolution magnification endoscopy with NBI allows clear visualisation of microstructural and microvascular patterns within Barrett's oesophagus, and allows targeted biopsy with a high yield of SIM and high grade dysplasia.
  • [MeSH-major] Barrett Esophagus / diagnosis. Esophagoscopy / methods. Metaplasia / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Esophagitis, Peptic / etiology. Female. Humans. Male. Middle Aged. Precancerous Conditions / diagnosis. Reproducibility of Results. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17635385.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Oh DS, DeMeester SR, Vallbohmer D, Mori R, Kuramochi H, Hagen JA, Lipham J, Danenberg KD, Danenberg PV, Chandrasoma P, DeMeester TR: Reduction of interleukin 8 gene expression in reflux esophagitis and Barrett's esophagus with antireflux surgery. Arch Surg; 2007 Jun;142(6):554-9; discussion 559-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduction of interleukin 8 gene expression in reflux esophagitis and Barrett's esophagus with antireflux surgery.
  • Twenty patients did not have reflux or mucosal injury; 47 had reflux disease (16 esophagitis and 31 Barrett's esophagus), 20 had dysplasia, and 21 had adenocarcinoma.
  • Patients with the highest IL-8 expression were those with Barrett's dysplasia and adenocarcinoma (P<.001).
  • In patients with reflux, Nissen fundoplication led to significantly decreased IL-8 expression compared with preoperative levels in esophagitis (P = .01) and Barrett's esophagus (P = .03).
  • Elimination of reflux with Nissen fundoplication significantly reduces IL-8 expression in both squamous and Barrett's mucosa.
  • [MeSH-major] Adenocarcinoma / metabolism. Barrett Esophagus / metabolism. Esophageal Neoplasms / metabolism. Esophagitis, Peptic / metabolism. Fundoplication. Interleukin-8 / metabolism

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17576892.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-8; 0 / RNA, Messenger
  •  go-up   go-down


10. Shaheen NJ: Advances in Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology; 2005 May;128(6):1554-66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in Barrett's esophagus and esophageal adenocarcinoma.
  • This review focuses on the epidemiology of esophageal adenocarcinoma and its presumed precursor lesion, Barrett's esophagus; the pathogenesis of the cancer; advances in treatment of adenocarcinoma and Barrett's esophagus; and strategies for cancer prevention.
  • Recent evidence suggests that Barrett's esophagus is more prevalent in asymptomatic individuals than previously appreciated.
  • The pathogenesis of Barrett's esophagus is poorly understood.
  • Given that some subjects will have repeated bouts of severe erosive esophagitis and never develop Barrett's esophagus, host factors must play an important role.
  • Ablative therapies, as well as endoscopic mucosal resection, hold promise for those with superficial cancer or high-grade dysplasia.
  • The value of chemoprevention in subjects with dysplastic Barrett's esophagus by use of cyclooxygenase 2 inhibitors, nonsteroidal anti-inflammatory drugs, or proton pump inhibitors is unknown.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Barrett Esophagus / pathology. Barrett Esophagus / therapy. Esophageal Neoplasms / pathology. Esophageal Neoplasms / therapy

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15887151.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / K23DK59311-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 130
  •  go-up   go-down


11. Ida S: [Barrett's esophagus in children]. Nihon Rinsho; 2005 Aug;63(8):1454-7
Genetic Alliance. consumer health - Barrett's Esophagus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Barrett's esophagus in children].
  • Barrett's esophagus (BE) is a condition of esophageal dysplasia in which the tubular esophagus is lined with columnar instead of squamous mucosa--not with just any type of columnar mucosa, but with a specialized type with goblet cells.
  • 3 had intestinal dysplasia with goblet cells (BE).
  • The % time of pH under 4 on 24-hour pH monitoring was significantly lower in the patients with esophagitis including BE than in them with normal esophagus.
  • [MeSH-major] Barrett Esophagus

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16101239.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Proton Pump Inhibitors
  • [Number-of-references] 13
  •  go-up   go-down


12. Ormeci N, Savas B, Coban S, Palabiyikoğlu M, Ensari A, Kuzu I, Kursun N: The usefulness of chromoendoscopy with methylene blue in Barrett's metaplasia and early esophageal carcinoma. Surg Endosc; 2008 Mar;22(3):693-700
Hazardous Substances Data Bank. METHYLENE BLUE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The usefulness of chromoendoscopy with methylene blue in Barrett's metaplasia and early esophageal carcinoma.
  • BACKGROUND: Barrett's esophagus is a condition that is premalignant for adenocarcinoma of the esophagus and the esophagogastric junction.
  • Early detection of Barrett's metaplasia and dysplasia is very important to decrease the mortality and morbidity from esophageal adenocarcinoma cancer.
  • This study aimed to evaluate the effectiveness of methylene blue-targeted biopsies in the differential diagnosis of intestinal metaplasia, dysplasia, and superficial esophageal carcinoma.
  • The sensitivity of chromoendoscopy for Barrett's epithelium was superior to that of conventional endoscopy (p < 0.05).
  • However, there was no statistical difference between the two methods in the diagnosis of esophagitis or esophageal carcinoma (p > 0.05).
  • Stained biopsies were superior to unstained biopsies in terms of sensitivity for Barrett's epithelium and esophageal carcinoma (p < 0.001).
  • CONCLUSION: Chromoendoscopy is useful for delineating Barrett's epithelium and for indicating the correct location for securing biopsies where dysplasia or early esophageal cancer is suspected.
  • [MeSH-major] Barrett Esophagus / pathology. Carcinoma, Squamous Cell / pathology. Esophageal Neoplasms / pathology. Esophagoscopy / methods. Methylene Blue. Precancerous Conditions / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17704887.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] T42P99266K / Methylene Blue
  •  go-up   go-down


13. Csendes A, Burgos AM, Smok G, Burdiles P, Henriquez A: Effect of gastric bypass on Barrett's esophagus and intestinal metaplasia of the cardia in patients with morbid obesity. J Gastrointest Surg; 2006 Feb;10(2):259-64
MedlinePlus Health Information. consumer health - Weight Loss Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of gastric bypass on Barrett's esophagus and intestinal metaplasia of the cardia in patients with morbid obesity.
  • Five hundred fifty-seven patients with morbid obesity submitted to resectional gastric bypass, and routine preoperative upper endoscopy with biopsy samples demonstrated 12 patients with Barrett's esophagus (2.1%) and three patients with intestinal metaplasia of the cardia (CIM).
  • An endoscopic procedure was repeated twice after surgery, producing seven patients with short-segment Barrett's esophagus (BE) and five patients with long-segment BE.
  • Symptoms of reflux esophagitis, which were present in 14 of the 15 patients, disappeared in all patients 1 year after surgery.
  • Preoperative erosive esophagitis and peptic ulcer of the esophagus healed in all patients.
  • There was no progression to low- or high-grade dysplasia.
  • Gastric bypass in patients with Barrett's esophagus and morbid obesity is an excellent antireflux operation, proved by the disappearance of symptoms and the healing of endoscopic esophagitis or peptic ulcer in all patients, which is followed by an important regression to cardiac mucosa that is length-dependent and time-dependent.
  • [MeSH-major] Barrett Esophagus / therapy. Cardia / pathology. Gastric Bypass. Intestinal Mucosa / pathology. Obesity, Morbid / surgery
  • [MeSH-minor] Adult. Biopsy. Body Mass Index. Esophageal pH Monitoring. Esophagitis, Peptic / therapy. Esophagoscopy. Female. Follow-Up Studies. Gastric Mucosa / pathology. Gastroscopy. Humans. Male. Metaplasia. Middle Aged. Prospective Studies. Time Factors. Wound Healing / physiology

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • Genetic Alliance. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16455459.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Schmassmann A, Gebbers JO: [Barrett's esophagus: diagnosis and therapy]. Praxis (Bern 1994); 2005 May 25;94(21):861-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Barrett's esophagus: diagnosis and therapy].
  • [Transliterated title] Barrett-Osophagus: Diagnostik und Therapie.
  • Barrett's esophagus is usually diagnosed by the endoscopic and histological finding of columnar epithelium with intestinal metaplasia in the distal esophagus.
  • The prevalence of Barrett's esophagus (long segment) is <2% in the general population and 3-5% in patients with chronic reflux symptoms.
  • Barrett mucosa predisposes patients to adenocarcinoma that develops in approximately 0.5% of these patients per year (Barrett mucosa --> dysplasia --> cancer sequence).
  • The malignant potential of the Barrett mucosa increases with dysplastic changes.
  • [MeSH-major] Adenocarcinoma / diagnosis. Barrett Esophagus / diagnosis. Esophageal Neoplasms / diagnosis. Precancerous Conditions / diagnosis
  • [MeSH-minor] Adult. Biopsy. Cell Transformation, Neoplastic / pathology. Esophagitis, Peptic / complications. Esophagitis, Peptic / pathology. Esophagitis, Peptic / therapy. Esophagoscopy. Esophagus / pathology. Female. Follow-Up Studies. Humans. Intestinal Mucosa / pathology. Male. Metaplasia. Middle Aged. Practice Guidelines as Topic

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966485.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


15. Leeuwenburgh I, Haringsma J, Van Dekken H, Scholten P, Siersema PD, Kuipers EJ: Long-term risk of oesophagitis, Barrett's oesophagus and oesophageal cancer in achalasia patients. Scand J Gastroenterol Suppl; 2006;(243):7-10
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term risk of oesophagitis, Barrett's oesophagus and oesophageal cancer in achalasia patients.
  • The treatment is symptomatic, aimed at lowering of the LOS pressure, and may be accompanied by various side effects, including gastro-oesophageal reflux, a risk factor for oesophagitis and its complications.
  • Stasis and fermentation can also lead to inflammation of the oesophageal mucosa, giving rise to hyperplasia of the epithelium, multifocal dysplasia and in some patients eventually squamous cell carcinoma.
  • Unfortunately, the sensitivity and specificity of endoscopical inspection to assess inflammation or dysplasia of the oesophageal lining is low, such that biopsy sampling is necessary for accurate assessment.
  • In addition, achalasia may predispose to Barrett's metaplasia and oesophageal adenocarcinoma, which have been described in case reports after myotomy.
  • [MeSH-major] Barrett Esophagus / etiology. Esophageal Achalasia / complications. Esophageal Neoplasms / etiology. Esophagitis / etiology

  • Genetic Alliance. consumer health - Achalasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16782616.001).
  • [ISSN] 0085-5928
  • [Journal-full-title] Scandinavian journal of gastroenterology. Supplement
  • [ISO-abbreviation] Scand. J. Gastroenterol. Suppl.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Norway
  • [Number-of-references] 35
  •  go-up   go-down


16. Kroshchuk VV, Miasoiedov SD, Andreieshchev SA, Buryĭ OM, Fediuchek AS, Umanets' MS, Petunin IuI, Oleksiuk OV: [Remote results of the treatment of patients for Barrett's esophagus]. Klin Khir; 2010 May;(5):5-10
Genetic Alliance. consumer health - Barrett's Esophagus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Remote results of the treatment of patients for Barrett's esophagus].
  • Prospective analysis of the results of clinic-laboratory investigations in patients, treated for Barrett's esophagus (BE) in 2000 - 2006 yrs, was conducted.
  • Higher efficacy of surgical method was established concerning the treatment of hiatal hernia, shortened esophagus, reflux-esophagitis, gastroesophageal and duodenogastric refluxes, duodenal ulcer and esophageal epithelium dysplasia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20626108.001).
  • [ISSN] 0023-2130
  • [Journal-full-title] Klinichna khirurhiia
  • [ISO-abbreviation] Klin Khir
  • [Language] UKR
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Antacids
  •  go-up   go-down


17. Inayama M, Hashimoto N, Tokoro T, Shiozaki H: Involvement of oxidative stress in experimentally induced reflux esophagitis and esophageal cancer. Hepatogastroenterology; 2007 Apr-May;54(75):761-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involvement of oxidative stress in experimentally induced reflux esophagitis and esophageal cancer.
  • All animals underwent an esophagoduodenal anastomosis (EDA) with total gastrectomy in order to produce chronic esophagitis.
  • Their esophagi were examined for the presence of cancer, Barrett's esophagus (BE), columnar line epithelium (CLE) and oxidative stress.
  • RESULTS: After 35 weeks of reflux, columnar dysplasia and squamous carcinoma were found.
  • To discover the role of oxidative stress and radical scavenger capacity in the malignant transformation of Barrett's esophagus, we measured Malondialdehyde (MDA), Superoxide dismutase (SOD) activity and Glutathione (GSH) content in EDA rats.
  • [MeSH-major] Carcinoma, Squamous Cell / etiology. Esophageal Neoplasms / etiology. Esophagitis, Peptic / complications. Oxidative Stress

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17591057.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 4Y8F71G49Q / Malondialdehyde; EC 1.15.1.1 / Superoxide Dismutase; GAN16C9B8O / Glutathione
  •  go-up   go-down


18. Buskens CJ, Hulscher JB, van Gulik TM, Ten Kate FJ, van Lanschot JJ: Histopathologic evaluation of an animal model for Barrett's esophagus and adenocarcinoma of the distal esophagus. J Surg Res; 2006 Oct;135(2):337-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathologic evaluation of an animal model for Barrett's esophagus and adenocarcinoma of the distal esophagus.
  • INTRODUCTION: Barrett's esophagus and adenocarcinoma of the esophagus are related to long-standing duodeno-gastroesophageal reflux.
  • The development of an animal model in which Barrett's esophagus and/or carcinoma is induced by duodeno-(gastro-)esophageal reflux could provide better understanding of the pathogenesis of the metaplasia-dysplasia-carcinoma sequence and would create the possibility of investigating new treatment strategies for this aggressive disease.
  • Sequential morphological changes (i.e., esophagitis, intestinal metaplasia, dysplasia, and carcinoma) were studied after 4, 6, and 12 months.
  • Severe ulcerative esophagitis was seen in all animals, with a 2-mm segment of metaplastic epithelium found at the anastomosis.
  • In these animals, extensive esophagitis with squamous cell hyperplasia was found.
  • In addition, a short (2 mm) segment of metaplastic epithelium was observed, without dysplasia.
  • After 1 year, 9 of the 10 animals had developed a glandular metaplastic segment (median length, 10 mm), which was histologically and immunohistologically characteristic for the specialized columnar epithelium of Barrett's esophagus without signs of dysplasia.
  • Although they showed cytological characteristics of malignancy, histopathologic evaluation was more suggestive of a reactive mucous producing lesion fitting the diagnosis "esophagitis cystica profunda."
  • CONCLUSION: This study demonstrates the development of a long Barrett's segment in an animal duodeno-gastroesophageal reflux model.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Disease Models, Animal. Esophageal Neoplasms / pathology. Gastrointestinal Tract / surgery


19. Alcedo J, Ferrández A, Arenas J, Sopeña F, Ortego J, Sainz R, Lanas A: Trends in Barrett's esophagus diagnosis in Southern Europe: implications for surveillance. Dis Esophagus; 2009;22(3):239-48
Genetic Alliance. consumer health - Barrett's Esophagus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in Barrett's esophagus diagnosis in Southern Europe: implications for surveillance.
  • The incidence of Barrett's esophagus (BE) and esophageal adenocarcinoma has increased in Western countries in recent decades.
  • The aim of this study is to describe the changes in incidence and prevalence of BE diagnosis, dysplasia, and adenocarcinoma development in BE patients in a South-European Mediterranean area.
  • The incidence of dysplasia was 2.13% per year (95% confidence interval: 0.05-11.3%) - 1.78% for low-grade dysplasia and 0.36% for high-grade dysplasia - giving a total incidence of 1 per 47 patient-years.
  • Progression to low-grade dysplasia and adenocarcinoma is rare.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19425201.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


20. Demura TA, Kogan EA, Sklianskaia OA, Mol' R: [Role of tight junction claudins in the morphogenesis of adenocarcinoma in the presence of Barrett's esophagus]. Arkh Patol; 2008 Sep-Oct;70(5):20-4
MedlinePlus Health Information. consumer health - GERD.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Role of tight junction claudins in the morphogenesis of adenocarcinoma in the presence of Barrett's esophagus].
  • The purpose of the investigation was to study a role of tight junction (TJ) claudins (CL) in the morphogenesis of adenocarcinoma (AC) in the presence of Barrett's esophagus (BE).
  • 1) GERD-esophagitis (a control group, n = 10);.
  • 2) GERD-esophagitis with gastric metaplasia (n = 15);.
  • 3) BE with enteric metaplasia (EM) without dysplasia (n = 9);.
  • 4) BE with colonic metaplasia (CM) without dysplasia (n = 9);.
  • 5) BE with varying dysplasia (the latter being detected in the presence of CM (n = 10);.
  • Transition of low- to high-grade dysplasia and to AC into BE was established to be accompanied by TJ loss, as appeared as disappearance of apical staining of Cl 1, 2, 3, 4, 5, and 7; moreover, their cytoplasmic staining increased in parallel.
  • The markers of cell differentiation of Cl 1, 2, 3, 4, 5, and 7 may be recommended for determination of the malignant potential of dysplasia to BE.
  • [MeSH-major] Adenocarcinoma / etiology. Barrett Esophagus / complications. Esophageal Neoplasms / etiology. Gastroesophageal Reflux / complications. Membrane Proteins / metabolism. Tight Junctions / metabolism

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19137778.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Membrane Proteins
  •  go-up   go-down


21. Weimann A, Zimmermann M, Gross M, Slevogt H, Rieger A, Morawietz L: CDX2 and LI-cadherin expression in esophageal mucosa: use of both markers can facilitate the histologic diagnosis of Barrett's esophagus and carcinoma. Int J Surg Pathol; 2010 Oct;18(5):330-7
Genetic Alliance. consumer health - Barrett's Esophagus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CDX2 and LI-cadherin expression in esophageal mucosa: use of both markers can facilitate the histologic diagnosis of Barrett's esophagus and carcinoma.
  • BACKGROUND: Barrett's mucosa is a risk factor for esophageal adenocarcinoma and should be detected at an early stage.
  • Aberrant CDX2 expression has been demonstrated in Barrett's metaplasia, esophagitis, and intestinal metaplasia of the stomach.
  • METHODS: The relationship between CDX2 and LI-cadherin expression was investigated in normal gastroesophageal (n = 24) and in Barrett's (n = 20) mucosa, in low-grade (n = 15) and high-grade (n = 13) intraepithelial neoplasia (IEN) as well as in esophageal adenocarcinoma (n = 16), using immunohistochemistry.
  • RESULTS: Nuclear positivity for CDX2 coupled with membranous expression of LI-cadherin was observed in about 70% of the epithelial cells of Barrett's mucosa.
  • CONCLUSIONS: CDX2 and LI-cadherin are sensitive markers of intestinal metaplasia with or without dysplasia in the upper gastrointestinal tract.
  • Both can be helpful for the early histologic diagnosis of Barrett's esophagus and its subsequent lesions; however, they do not significantly discern between different grades of dysplasia.
  • [MeSH-major] Adenocarcinoma / diagnosis. Barrett Esophagus / diagnosis. Biomarkers / metabolism. Cadherins / metabolism. Homeodomain Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20444732.001).
  • [ISSN] 1940-2465
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CDH17 protein, human; 0 / CDX2 protein, human; 0 / Cadherins; 0 / Homeodomain Proteins
  •  go-up   go-down


22. Majka J, Rembiasz K, Migaczewski M, Budzynski A, Ptak-Belowska A, Pabianczyk R, Urbanczyk K, Zub-Pokrowiecka A, Matlok M, Brzozowski T: Cyclooxygenase-2 (COX-2) is the key event in pathophysiology of Barrett's esophagus. Lesson from experimental animal model and human subjects. J Physiol Pharmacol; 2010 Aug;61(4):409-18
Genetic Alliance. consumer health - Barrett's Esophagus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclooxygenase-2 (COX-2) is the key event in pathophysiology of Barrett's esophagus. Lesson from experimental animal model and human subjects.
  • Mixed reflux of the gastroduodenal contents induces the esophageal mucosal damage and inflammation progressing chronic esophagitis and premalignant Barrett's esophagus (BE).
  • In experimental studies, eighty rats were surgically prepared with esophagogastroduodenal anastomosis (EGDA) resulting in chronic esophagitis.
  • Chronic esophagitis was developed in all EGDA animals followed by the rise in the plasma TNF-alpha and IL-1beta levels.
  • COX-2 mRNA was absent in the esophageal mucosa of sham-control animals but strongly upregulated in metaplastic Barrett's epithelium.
  • In BE patients, the overexpression of COX-2 was documented in patients with dysplasia.
  • We conclude that 1) EGDA rats serve as the suitable model of the chronic esophagitis by the gastrointestinal refluxate resembling many features of those observed in human Barrett's esophagus, as confirmed by severe morphology changes, excessive release of proinflammatory cytokines TNF-alpha and IL-1beta and overexpression of COX-2, and 2) the significant correlation of the degree of COX-2 overexpression with histopathological findings indicates the usefulness of this inducible biomarker as a valuable indicator of the risk of malignant transformation in patients with BE.
  • [MeSH-major] Barrett Esophagus / enzymology. Barrett Esophagus / physiopathology. Cyclooxygenase 2 / physiology. Disease Models, Animal

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20814068.001).
  • [ISSN] 1899-1505
  • [Journal-full-title] Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  • [ISO-abbreviation] J. Physiol. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


23. Xiong LS, Cui Y, Wang JP, Wang JH, Xue L, Hu PJ, Chen MH: Prevalence and risk factors of Barrett's esophagus in patients undergoing endoscopy for upper gastrointestinal symptoms. J Dig Dis; 2010 Apr;11(2):83-7
Genetic Alliance. consumer health - Barrett's Esophagus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and risk factors of Barrett's esophagus in patients undergoing endoscopy for upper gastrointestinal symptoms.
  • OBJECTIVE: To investigate the prevalence of Barrett's esophagus (BE) and its risk factors in patients undergoing endoscopy for upper gastrointestinal symptoms in a Chinese tertiary referral medical center.
  • One of the 21 patients had low-grade dysplasia.
  • By logistic multivariate analysis, age (OR 1.03; 95% CI, 1.00, 1.07) and reflux esophagitis (OR 4.44; 95% CI, 1.22, 16.17) were factors associated significantly with BE.
  • Older age and reflux esophagitis may be the risk factors for developing BE.
  • [MeSH-major] Barrett Esophagus / epidemiology. Barrett Esophagus / pathology. Endoscopy, Gastrointestinal. Upper Gastrointestinal Tract / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20402833.001).
  • [ISSN] 1751-2980
  • [Journal-full-title] Journal of digestive diseases
  • [ISO-abbreviation] J Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


24. Chang Y, Liu B, Liu GS, Wang T, Gong J: Short-segment Barrett's esophagus and cardia intestinal metaplasia: A comparative analysis. World J Gastroenterol; 2010 Dec 28;16(48):6151-4
Genetic Alliance. consumer health - Barrett's Esophagus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short-segment Barrett's esophagus and cardia intestinal metaplasia: A comparative analysis.
  • AIM: to investigate the endoscopy and histology of short-segment Barrett's esophagus (SSBE) and cardia intestinal metaplasia (CIM), and their correlation with Helicobacter pylori (H. pylori) gastritis and gastroesophageal reflux disease (GERD).
  • The incidence of dysplasia and incomplete intestinal metaplasia subtype was higher in SSBE patients than in CIM patients (P < 0.01). H. pylori infection was correlated with antral intestinal metaplasia (P < 0.05), but not with reflux symptomatic, endoscopic, or histological markers of GERD in CIM patients.
  • SSBE was correlated with reflux symptomatic and endoscopic esophagitis (P < 0.01), but not with H. pylori infection and antral intestinal metaplasia.
  • CONCLUSION: dysplasia risk is significantly greater in SSBE patients than in CIM patients.
  • [MeSH-major] Barrett Esophagus / pathology. Cardia / pathology. Intestines / pathology. Metaplasia / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 1999 Nov;12(11):1017-24 [10574598.001]
  • [Cites] World J Gastroenterol. 2010 Feb 7;16(5):531-7 [20128019.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2520-8 [10861428.001]
  • [Cites] Acta Gastroenterol Belg. 2000 Jan-Mar;63(1):13-7 [10907313.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):26-33 [11781277.001]
  • [Cites] J Clin Pathol. 2002 Mar;55(3):191-4 [11896070.001]
  • [Cites] Neoplasia. 2002 Mar-Apr;4(2):121-8 [11896567.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Apr;19(4):357-67 [15012771.001]
  • [Cites] World J Gastroenterol. 2004 Apr 1;10(7):1065-8 [15052695.001]
  • [Cites] World J Gastroenterol. 2004 Nov 1;10(21):3194-6 [15457573.001]
  • [Cites] Hum Pathol. 1988 Aug;19(8):942-8 [3402983.001]
  • [Cites] Lancet. 1994 Dec 3;344(8936):1533-6 [7983953.001]
  • [Cites] Science. 1995 Oct 20;270(5235):467-70 [7569999.001]
  • [Cites] Am J Gastroenterol. 1997 Mar;92(3):414-8 [9068460.001]
  • [Cites] Gut. 1998 May;42(5):659-62 [9659160.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2037-42 [10445525.001]
  • [Cites] Gut. 1999 Nov;45(5):644-8 [10517897.001]
  • [Cites] World J Gastroenterol. 2005 Jun 21;11(23):3558-61 [15962374.001]
  • [Cites] Endoscopy. 2005 Sep;37(9):879-920 [16116544.001]
  • [Cites] World J Gastroenterol. 2005 Oct 28;11(40):6360-5 [16419166.001]
  • [Cites] Dis Esophagus. 2009;22(4):348-53 [19191861.001]
  • [Cites] World J Gastroenterol. 2010 Jan 28;16(4):484-9 [20101776.001]
  • [Cites] Gut. 2000 Jan;46(1):9-13 [10601047.001]
  • (PMID = 21182233.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC3012569
  •  go-up   go-down


25. O'Riordan JM, Abdel-latif MM, Ravi N, McNamara D, Byrne PJ, McDonald GS, Keeling PW, Kelleher D, Reynolds JV: Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Gastroenterol; 2005 Jun;100(6):1257-64
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
  • Most cases arise in a background of chronic gastroesophageal reflux, and specialized intestinal metaplasia in Barrett's esophagus is frequently an antecedent phenotype or evident in association with adenocarcinoma.
  • The molecular events that characterize the pathway from inflammation to metaplasia to dysplasia and adenocarcinoma are poorly understood.
  • AIMS: To examine the expression of the proinflammatory cytokines IL-8 and IL-1beta along the esophagitis, metaplasia, dysplasia, and adenocarcinoma pathway, and to correlate this with histological changes and expression of the transcription factor NF-kappaB.
  • PATIENTS AND METHODS: Fresh biopsy specimens were collected from patients with reflux esophagitis (n=15), Barrett's esophagus (n=35), Barrett's adjacent to adenocarcinoma (n=8), and esophageal adenocarcinoma (n=35).
  • RESULTS: Elevated expression of NF-kappaB was found in 2 (13%) out of 15 patients with reflux esophagitis, 21 (60%) out of 35 patients with Barrett's esophagus, and 28 (80%) out of 35 patients with esophageal adenocarcinoma.
  • All 5 patients with Barrett's esophagus and high-grade dysplasia showed elevated expression of NF-kappaB.
  • IL-8 and IL-1beta were significantly increased in esophagitis, Barrett's, and adenocarcinoma compared with squamous epithelium, and in adenocarcinoma compared with all other groups.
  • There was a stepwise increase in the expression of IL-8, IL-1beta, and NF-kappaB from normal through Barrett's epithelium to adenocarcinoma in eight cases of esophageal adenocarcinoma.
  • CONCLUSIONS: The proinflammatory cytokines IL-8 and IL-1beta are elevated in esophagitis and Barrett's epithelium, and markedly elevated in adenocarcinoma.
  • NF-kappaB activation is infrequent in esophagitis, but is increased in Barrett's epithelium and adenocarcinoma.
  • These patterns may play an important role in Barrett's inflammation and tumourigenesis, and inhibition of the NF-kappaB/proinflammatory cytokine pathway may be an important target for future chemoprevention strategies.
  • [MeSH-major] Adenocarcinoma / metabolism. Esophageal Neoplasms / metabolism. Esophagitis / metabolism. Interleukin-1 / biosynthesis. Interleukin-8 / biosynthesis. NF-kappa B / biosynthesis
  • [MeSH-minor] Barrett Esophagus / metabolism. Barrett Esophagus / pathology. Biomarkers / metabolism. Biopsy. Electrophoresis. Endoscopy, Digestive System. Enzyme-Linked Immunosorbent Assay. Female. Gastroesophageal Reflux / metabolism. Gastroesophageal Reflux / pathology. Humans. Intestinal Mucosa / metabolism. Intestinal Mucosa / pathology. Male. Metaplasia / metabolism. Metaplasia / pathology. Middle Aged. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Prospective Studies

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15929754.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Interleukin-1; 0 / Interleukin-8; 0 / NF-kappa B
  •  go-up   go-down


26. Hoffmann KM, Gibril F, Entsuah LK, Serrano J, Jensen RT: Patients with multiple endocrine neoplasia type 1 with gastrinomas have an increased risk of severe esophageal disease including stricture and the premalignant condition, Barrett's esophagus. J Clin Endocrinol Metab; 2006 Jan;91(1):204-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with multiple endocrine neoplasia type 1 with gastrinomas have an increased risk of severe esophageal disease including stricture and the premalignant condition, Barrett's esophagus.
  • Although esophageal reflux symptoms are common in these patients, little is known about long-term occurrence of severe peptic esophageal disease including strictures and Barrett's esophagus (BE).
  • RESULTS: In MEN1/ZES patients, esophageal stricture was 3-fold higher, BE 5-fold higher, and dysplasia 8-fold higher, and one patient died of esophageal adenocarcinoma.
  • MEN1/ZES patients with esophageal disease differed from those without in that ZES diagnosis was delayed longer, esophageal symptoms were more frequent or severe, hiatal hernias were more frequent, esophagitis or pyloric scarring was more common, basal acid output was higher, and hyperparathyroidism was underdiagnosed.
  • [MeSH-major] Barrett Esophagus / epidemiology. Barrett Esophagus / etiology. Esophageal Diseases / epidemiology. Esophageal Diseases / etiology. Esophageal Stenosis / epidemiology. Esophageal Stenosis / etiology. Gastrinoma / complications. Multiple Endocrine Neoplasia Type 1 / complications


27. Gough MD, Ackroyd R, Majeed AW, Bird NC: Prediction of malignant potential in reflux disease: are cytokine polymorphisms important? Am J Gastroenterol; 2005 May;100(5):1012-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Esophageal reflux is common in the Western world and can lead to a number of diseases, such as esophagitis, Barrett's esophagus, and adenocarcinoma.
  • Barrett's predisposes to adenocarcinoma and endoscopic surveillance may lead to earlier detection of adenocarcinoma.
  • However, clinical methods only identify one patient in 15 with Barrett's esophagus.
  • The aim of this study was to find factors that may help identify patients with Barrett's earlier.
  • METHODS: Blood samples and detailed histories were taken from 456 patients with gastroesophageal reflux who were recruited into three study groups: esophagitis, Barrett's esophagus without dysplasia, and Barrett's with dysplasia or adenocarcinoma.
  • RESULTS: IL-1 Ra +2018 genotype 2/2 was associated with Barrett's more commonly than esophagitis (OR-3.7, p= 0.0345).
  • The IL-10 +1082 genotype 2/2 was more strongly associated with Barrett's and adenocarcinoma than esophagitis (OR-1.76, p= 0.056 and OR 1.96, p= 0.025, respectively).
  • CONCLUSIONS: Cytokine polymorphisms are more commonly found in patients with Barrett's or adenocarcinoma than those with esophagitis.
  • Together with demographic data, this may help identify those patients with Barrett's who would benefit from surveillance.
  • [MeSH-minor] Adenocarcinoma / etiology. Adenocarcinoma / immunology. Adult. Aged. Aged, 80 and over. Barrett Esophagus / etiology. Barrett Esophagus / immunology. Esophagitis, Peptic / etiology. Esophagitis, Peptic / immunology. Female. Forecasting. Genotype. Humans. Interleukin-1 / genetics. Interleukin-10 / genetics. Male. Middle Aged. Polymerase Chain Reaction. Receptors, Interleukin-1 / antagonists & inhibitors. Receptors, Interleukin-4 / genetics

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - GERD.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Gastroenterol. 2005 May;100(5):1019-20 [15842573.001]
  • (PMID = 15842572.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-1; 0 / Interleukins; 0 / Receptors, Interleukin-1; 0 / Receptors, Interleukin-4; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10
  •  go-up   go-down


28. Leodolter A, Penagini R: On-demand therapy is a valid strategy in GERD patients: pros and cons. Dig Dis; 2007;25(3):175-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On-demand treatment is less cost-saving in patients with esophagitis, and symptomatic/endoscopic relapses occur frequently in severe grades.
  • It is suggested that PPI continuous maintenance is more appropriate than on-demand therapy in patients with severe esophagitis, in those with Barrett's esophagus where chronic PPIs may reduce incidence of dysplasia, in uninvestigated elderly patients where esophagitis is more prevalent and it is more frequently complicated with gastrointestinal bleeding and possibly in uninvestigated or NERD patients with frequent clinical relapses.
  • [MeSH-minor] Aged. Barrett Esophagus / drug therapy. Esophagitis, Peptic / drug therapy. Humans

  • MedlinePlus Health Information. consumer health - GERD.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 S. Karger AG, Basel
  • (PMID = 17827935.001).
  • [ISSN] 1421-9875
  • [Journal-full-title] Digestive diseases (Basel, Switzerland)
  • [ISO-abbreviation] Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Proton Pump Inhibitors
  •  go-up   go-down


29. Vakil N: Increasing compliance with long-term therapy: avoiding complications and adverse events. Rev Gastroenterol Disord; 2005;5 Suppl 2:S12-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, continuous medical therapy for erosive esophagitis is associated with fewer relapses and better outcomes.
  • Similarly, long-term therapy administered continuously reduces complications such as stricture and may decrease the development of dysplasia in Barrett's esophagus.
  • [MeSH-major] Barrett Esophagus / drug therapy. Gastroesophageal Reflux / drug therapy. Patient Compliance. Proton Pump Inhibitors

  • MedlinePlus Health Information. consumer health - GERD.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16369223.001).
  • [ISSN] 1533-001X
  • [Journal-full-title] Reviews in gastroenterological disorders
  • [ISO-abbreviation] Rev Gastroenterol Disord
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gastrointestinal Agents; 0 / Proton Pump Inhibitors
  • [Number-of-references] 27
  •  go-up   go-down


30. Wang W, Zhang ZJ, Lin KR, Li DZ, Wen XD, Wu QP: [The prevalence, clinical and endoscopic characteristics of Barrett esophagus in Fujian]. Zhonghua Nei Ke Za Zhi; 2006 May;45(5):393-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The prevalence, clinical and endoscopic characteristics of Barrett esophagus in Fujian].
  • OBJECTIVE: To investigate the incidence and clinical and endoscopic characteristics of Barrett's esophagus (BE) and the relationship between BE and reflux esophagitis (RE).
  • Intestinal metaplasia was detected in 34.83% of BE and dysplasia 9.88%.
  • [MeSH-major] Barrett Esophagus / diagnosis. Barrett Esophagus / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. China / epidemiology. Esophagitis, Peptic / diagnosis. Esophagitis, Peptic / pathology. Female. Gastroscopy. Helicobacter Infections / complications. Helicobacter pylori / isolation & purification. Humans. Male. Middle Aged. Prevalence. Sex Factors

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16780743.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


31. Csendes A, Burgos AM, Smok G, Beltran M: Endoscopic and histologic findings of the foregut in 426 patients with morbid obesity. Obes Surg; 2007 Jan;17(1):28-34
Genetic Alliance. consumer health - Obesity.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Pathological findings at the esophagus were seen in 55% of the patients, mainly related to reflux esophagitis.
  • Barrett's esophagus was seen in 5.8%.
  • Antral adenoma with low-grade dysplasia was found in 1 patient, and 1 carcinoid tumor. H. pylori was present in 53% of the patients, mainly in the antrum.
  • After surgery, if Barrett's esophagus was present, endoscopic surveillance is recommended.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Obes Surg. 2007 Jul;17(7):993; author reply 994 [17894165.001]
  • (PMID = 17355765.001).
  • [ISSN] 0960-8923
  • [Journal-full-title] Obesity surgery
  • [ISO-abbreviation] Obes Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


32. Chen MJ, Lee YC, Chiu HM, Wu MS, Wang HP, Lin JT: Time trends of endoscopic and pathological diagnoses related to gastroesophageal reflux disease in a Chinese population: eight years single institution experience. Dis Esophagus; 2010 Apr;23(3):201-7
MedlinePlus Health Information. consumer health - GERD.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The discrepancy between Eastern and Western countries exists regarding the time trends of Barrett's esophagus (BE)/adenocarcinoma.
  • Endoscopic detection of erosive esophagitis increased in referral populations from 1546 (20.7%) to 5207 cases (51%) and by screening endoscopy from 791 (14.5%) to 1983 cases (23.5%).
  • BE-associated dysplasia and adenocarcinoma were rare.
  • The detection of Los Angeles class A disease increased with time in referral endoscopy cases with a focus on erosive esophagitis composition.
  • The incidence of BE-associated dysplasia and adenocarcinoma has been the same and the increased screening did not detect more cancers.

  • Genetic Alliance. consumer health - Gastroesophageal Reflux.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19788438.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Siderits R, Hanna I, Baig Z, Godyn JJ: Sporadic ganglioneuromatosis of esophagogastric junction in a patient with gastro-esophageal reflux disorder and intestinal metaplasia. World J Gastroenterol; 2006 Dec 28;12(48):7874-7
MedlinePlus Health Information. consumer health - GERD.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 58-year-old female with a recurrent history of upper abdominal pain and intermittent dysphagia underwent endoscopic evaluation that demonstrated an irregular and nodular esophago-gastric (EG) junction and grade I erosive esophagitis.
  • Biopsies showed prominent intestinal metaplasia of Barrett's type without dysplasia, chronic inflammation and multiple aggregates of large cells within the mucosal lamina propria, some with spindle shaped nuclei.
  • The background of chronic inflammation with intestinal type metaplasia was consistent with long-term reflux esophagitis.

  • Genetic Alliance. consumer health - Esophageal Disorder.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1999 Oct;30(10):1213-20 [10534170.001]
  • [Cites] J Clin Pathol. 2002 Apr;55(4):318-20 [11919222.001]
  • [Cites] Pathol Res Pract. 2002;198(9):605-13 [12440783.001]
  • [Cites] J Formos Med Assoc. 2003 May;102(5):346-8 [12874676.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):431-6 [10199472.001]
  • [Cites] Aust N Z J Med. 1978 Oct;8(5):518-20 [33647.001]
  • [Cites] Cancer. 1996 Oct 15;78(8):1651-9 [8859176.001]
  • [Cites] Ann Thorac Surg. 1997 Oct;64(4):1173-4 [9354553.001]
  • [Cites] Gastrointest Radiol. 1978 Feb 23;2(4):327-30 [208910.001]
  • (PMID = 17203537.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4087559
  •  go-up   go-down


34. Herszenyi L, Hritz I, Pregun I, Sipos F, Juhasz M, Molnar B, Tulassay Z: Alterations of glutathione S-transferase and matrix metalloproteinase-9 expressions are early events in esophageal carcinogenesis. World J Gastroenterol; 2007 Feb 7;13(5):676-82
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To investigate the role of glutathione S-transferase (GST) and matrix metalloproteinase-9 (MMP-9) expressions in the development and progression of reflux esophagitis-Barrett's metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
  • METHODS: GST and MMP-9 expressions were analyzed in 51 paraffin-embedded tissue samples by immunohistochemistry including patients with reflux esophagitis (n = 7), Barrett's metaplasia (n = 14), Barrett and esophagitis (n = 8), Barrett and dysplasia (n = 7), esophageal adenocarcinoma (n = 8) and a control group without any histological changes (n = 7).
  • RESULTS: GST expression was significantly higher while MMP-9 expression was significantly lower in control group compared to Barrett's metaplasia and the other groups.
  • No major changes were observed between Barrett, esophagitis, and Barrett and concomitant esophagitis.
  • Barrett and concomitant dysplasia, and adenocarcinoma revealed a significant lower expression of GST and higher levels of MMP-9 compared to all other groups.
  • Adenocarcinoma showed almost no expression of GST and significantly higher levels of MMP-9 than Barrett and concomitant dysplasia.
  • CONCLUSION: Decreased GST and increased expression of MMP-9 in Barrett's metaplasia-dysplasia-adenocarcinoma sequence as compared to normal tissue suggest their association with esophageal tumorigenesis.
  • Loss of GST and gain of MMP-9 in Barrett with dysplasia compared to non-dysplastic metaplasia indicate that these alterations may be early events in carcinogenesis.
  • Quantification of these parameters in Barrett's esophagus might be useful to identify patients at higher risk for progression to cancer.
  • [MeSH-minor] Adult. Aged. Barrett Esophagus / epidemiology. Barrett Esophagus / metabolism. Barrett Esophagus / pathology. Female. Humans. Male. Middle Aged. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8229-34 [15623598.001]
  • [Cites] Carcinogenesis. 2004 Dec;25(12):2353-60 [15333466.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):620-5 [15767340.001]
  • [Cites] Orv Hetil. 2005 Feb 27;146(9):411-6 [15830608.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1554-66 [15887151.001]
  • [Cites] Oncologist. 2005 Sep;10(8):590-601 [16177283.001]
  • [Cites] World J Gastroenterol. 2005 Sep 28;11(36):5592-600 [16237750.001]
  • [Cites] World J Gastroenterol. 2005 Oct 21;11(39):6090-5 [16273632.001]
  • [Cites] Jpn J Clin Oncol. 2005 Dec;35(12):707-13 [16314343.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2006 Mar;18(3):277-82 [16462541.001]
  • [Cites] Anticancer Res. 2006 Mar-Apr;26(2B):1589-94 [16619576.001]
  • [Cites] Invest New Drugs. 2006 Mar;24(2):135-40 [16502351.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):1135-49 [10694567.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1169-74 [10741748.001]
  • [Cites] Gut. 2000 Jul;47(1):50-6 [10861264.001]
  • [Cites] Eur J Cancer. 2000 Oct;36(16):2164-70 [11044656.001]
  • [Cites] Lancet. 2000 Dec 16;356(9247):2079-85 [11145505.001]
  • [Cites] Mayo Clin Proc. 2001 Apr;76(4):438-46 [11322362.001]
  • [Cites] Br J Cancer. 2001 Aug 3;85(3):383-92 [11487270.001]
  • [Cites] J Gastrointest Surg. 2002 May-Jun;6(3):359-67 [12022988.001]
  • [Cites] Dis Esophagus. 2002;15(1):10-5 [12060037.001]
  • [Cites] J Clin Oncol. 2002 Jul 1;20(13):2971-9 [12089227.001]
  • [Cites] J Biol Chem. 2002 Dec 27;277(52):50326-32 [12384502.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2003 Jan;15(1):41-7 [12544693.001]
  • [Cites] World J Gastroenterol. 2003 May;9(5):899-904 [12717827.001]
  • [Cites] Jpn J Clin Oncol. 2003 Apr;33(4):186-91 [12810833.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Jan;130(1):37-44 [14569466.001]
  • [Cites] Dis Esophagus. 2004;17(1):67-70 [15209744.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5572-9 [15328199.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Oct;20 Suppl 5:71-80; discussion 95-6 [15456468.001]
  • [Cites] Crit Rev Biochem Mol Biol. 1990;25(1):47-70 [2182291.001]
  • [Cites] Cancer Res. 1991 Sep 15;51(18 Suppl):5054s-5059s [1884381.001]
  • [Cites] Cancer. 1992 Dec 15;70(12):2747-53 [1451050.001]
  • [Cites] Annu Rev Cell Biol. 1993;9:541-73 [8280471.001]
  • [Cites] Cancer. 1995 Aug 1;76(3):367-75 [8625115.001]
  • [Cites] J Biochem. 1996 Feb;119(2):209-15 [8882706.001]
  • [Cites] Carcinogenesis. 1996 Dec;17(12):2581-7 [9006092.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 May;6(5):369-77 [9149898.001]
  • [Cites] Jpn J Cancer Res. 1999 Jan;90(1):81-5 [10076569.001]
  • [Cites] Cancer. 1999 Oct 1;86(7):1135-42 [10506696.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Jan;3(1):1-10 [15645398.001]
  • (PMID = 17278189.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.5.1.18 / Glutathione Transferase; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ PMC4065999
  •  go-up   go-down


35. Maloney JD, Weigel TL: Minimally invasive esophagectomy for malignant and premalignant diseases of the esophagus. Surg Clin North Am; 2008 Oct;88(5):979-90, vi
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Minimally invasive approaches increasingly are used to treat esophageal cancer and Barrett's esophagitis with high-grade dysplasia.
  • [MeSH-major] Adenocarcinoma / surgery. Barrett Esophagus / surgery. Esophageal Neoplasms / surgery. Esophagectomy / methods. Laparoscopy. Thoracoscopy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18790149.001).
  • [ISSN] 0039-6109
  • [Journal-full-title] The Surgical clinics of North America
  • [ISO-abbreviation] Surg. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 32
  •  go-up   go-down


36. Micev M, Cosić-Micev M: [Pathology and pathobiology of the oesophageal carcinoma]. Acta Chir Iugosl; 2010;57(2):15-26
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Identification of dysplasia in mucosal biopsies is the most reliable pathologic indicator of an increased risk of development of squamous cell carcinoma and passes through the sequence of chronic esophagitis, low-grade and high-grade dysplasia and invasive carcinoma.
  • Although Barrett's esophagus is a precursor to esophageal adenocarcinoma and have a well described sequence of carcinogenesis: the Barrett's metaplasia-dysplasia-adenocarcinoma sequence, not all patients with this disorder require intensive surveillance.
  • The natural history of dysplasia is poorly understood, particularly in low-risk regions, and prospective follow-up studies are needed.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Barrett Esophagus / complications. Barrett Esophagus / pathology. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Humans

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20954310.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Serbia
  •  go-up   go-down


37. Woodall CE, Li Y, Liu QH, Wo J, Martin RC: Chemoprevention of metaplasia initiation and carcinogenic progression to esophageal adenocarcinoma by resveratrol supplementation. Anticancer Drugs; 2009 Jul;20(6):437-43
Hazardous Substances Data Bank. RESVERATROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The effects of resveratrol on the initiation of Barrett's metaplasia and the carcinogenic progression to esophageal adenocarcinoma have not been evaluated.
  • The aim of this study was to evaluate the effects of resveratrol on the transition from reflux esophagitis to Barrett's metaplasia to dysplasia to esophageal adenocarcinoma in an established rat model.
  • Thirty-one animals in the 5-month resveratrol group showed a decreased severity of esophagitis (P<0.0001), incidence of intestinal metaplasia (P = 0.3567), and incidence of carcinoma (P = 0.4590) as compared with both the saline and nonoperated control groups.
  • In conclusion, morphological characteristics consistent with decreased esophagitis and incidences of metaplasia and esophageal adenocarcinoma were seen on histopathology in the resveratrol group.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19398904.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Stilbenes; 0 / Thiobarbituric Acid Reactive Substances; EC 1.11.1.6 / Catalase; EC 1.15.1.1 / Superoxide Dismutase; GAN16C9B8O / Glutathione; Q369O8926L / resveratrol
  •  go-up   go-down


38. Li Y, Woodall C, Wo JM, Zheng H, Ng CK, Ray MB, Martin RC: The use of dynamic positron emission tomography imaging for evaluating the carcinogenic progression of intestinal metaplasia to esophageal adenocarcinoma. Cancer Invest; 2008 Apr-May;26(3):278-85
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In this study, we investigate the use of PET scanning in the carcinogenic progression of reflux esophagitis to Barrett's esophagus to high grade dysplasia to esophageal adenocarcinoma, and correlate the uptake levels of 18F-FDG related to histological changes, and the rates of proliferation and apoptosis.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Cell Transformation, Neoplastic / pathology. Esophageal Neoplasms / pathology. Positron-Emission Tomography. Precancerous Conditions / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18317969.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


39. Armstrong D, Marshall JK, Chiba N, Enns R, Fallone CA, Fass R, Hollingworth R, Hunt RH, Kahrilas PJ, Mayrand S, Moayyedi P, Paterson WG, Sadowski D, van Zanten SJ, Canadian Association of Gastroenterology GERD Consensus Group: Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. Can J Gastroenterol; 2005 Jan;19(1):15-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Uninvestigated heartburn-dominant dyspepsia - characterised by heartburn or acid regurgitation - includes erosive esophagitis or endoscopy-negative reflux disease, and may be treated empirically as GERD without further investigation provided there are no alarm features.
  • GERD is associated with Barrett's epithelium and esophageal adenocarcinoma but the risk of malignancy is very low.
  • Endoscopic screening for Barrett's epithelium may be considered in adults with GERD symptoms for more than 10 years; Barrett's epithelium and low-grade dysplasia generally warrant surveillance; endoscopic or surgical management should be considered for confirmed high-grade dysplasia or malignancy.
  • CONCLUSION: Prospective studies are needed to investigate clinically relevant risk factors for the development of GERD and its complications; GERD progression, on and off therapy; optimal management strategies for typical GERD symptoms in primary care patients; and optimal management strategies for atypical GERD symptoms, Barrett's epithelium and esophageal adenocarcinoma.
  • [MeSH-minor] Adult. Barrett Esophagus / diagnosis. Barrett Esophagus / etiology. Barrett Esophagus / therapy. Delphi Technique. Helicobacter Infections / complications. Helicobacter Infections / diagnosis. Helicobacter pylori. Humans. Severity of Illness Index

  • Genetic Alliance. consumer health - Gastroesophageal Reflux.
  • MedlinePlus Health Information. consumer health - GERD.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15685294.001).
  • [ISSN] 0835-7900
  • [Journal-full-title] Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • [ISO-abbreviation] Can. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Guideline; Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Canada
  • [Number-of-references] 308
  •  go-up   go-down


40. Vallböhmer D, DeMeester SR, Oh DS, Banki F, Kuramochi H, Shimizu D, Hagen JA, Danenberg KD, Danenberg PV, Chandrasoma PT, Peters JH, DeMeester TR: Antireflux surgery normalizes cyclooxygenase-2 expression in squamous epithelium of the distal esophagus. Am J Gastroenterol; 2006 Jul;101(7):1458-66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In some patients GERD presents with heartburn and regurgitation symptoms but a relative paucity of endoscopic and clinical findings, while in others symptoms may be minor or absent yet there is significant mucosal damage on endoscopy including the presence of Barrett's esophagus.
  • The initial injury of gastroesophageal reflux is to the squamous esophageal mucosa, but while substantial research has been devoted to determining which genes are involved in the progression of Barrett's to dysplasia and cancer, little is known about the gene expression alterations in the squamous mucosa of patients with reflux.
  • The presence of esophagitis or Barrett's esophagus did not significantly alter the expression of Cox-2 compared to patients with nonerosive reflux disease (NERD).
  • CONCLUSIONS: Cox-2 gene expression is increased in the distal esophageal squamous mucosa of most patients with GERD, and the elevation was similar whether there was mucosal injury in the form of esophagitis or Barrett's or no visible mucosal injury.

  • MedlinePlus Health Information. consumer health - GERD.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16863546.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA84424-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 63231-63-0 / RNA; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


41. Melstrom LG, Bentrem DJ, Salvino MJ, Blum MG, Talamonti MS, Printen KJ: Adenocarcinoma of the gastroesophageal junction after bariatric surgery. Am J Surg; 2008 Jul;196(1):135-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A retrospective review was conducted to identify patients who had undergone bariatric surgery (1999 to 2006) and who later developed high-grade dysplasia or adenocarcinoma of the distal esophagus.
  • CONCLUSIONS: Our findings emphasize the importance of precise endoscopic evaluation before bariatric surgery in patients with gastroesophageal reflux disease (GERD), of the necessity for continuing postsurgical surveillance in patients with known Barrett's esophagitis, and of early evaluation in patients who develop new symptoms of GERD after bariatric surgery.
  • [MeSH-minor] Aged. Barrett Esophagus / etiology. Gastroesophageal Reflux / etiology. Humans. Male. Middle Aged. Obesity, Morbid / complications. Obesity, Morbid / surgery. Retrospective Studies

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Weight Loss Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18417085.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Camilleri M: Gastroenterology and hepatology clinical research update: 2005-2006. Clin Gastroenterol Hepatol; 2006 Dec;4(12):1428-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The topics included eosinophilic esophagitis in children, detecting high-grade dysplasia or carcinoma in Barrett's esophagus, advances in management of celiac disease with elemental diet or gluten predigestion, the safety of NSAIDs in inflammatory bowel disease, the role of steroids in development of abscesses, prognosis of colorectal cancer associated with inflammatory bowel disease, screening for familial colorectal cancer in apparently sporadic disease, a new syndrome of familial colorectal cancer, new drugs in the treatment of chronic constipation and obesity, hepatoma risk factors and underserved racial/ethnic groups, and the application of new imaging and biology in diagnosis of gastroenterological disorders.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16949347.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 31
  •  go-up   go-down


43. Chlumská A, Boudová L, Benes Z, Zámecník M: Histopathologic changes in gastroesophageal reflux disease. A study of 126 bioptic and autoptic cases. Cesk Patol; 2007 Oct;43(4):142-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histologic diagnosis of reflux esophagitis is still complicated by the lack of a consensus opinion on what is the normal mucosa in the area of the gastroesophageal junction (GEJ).
  • In 17 cases, CM displayed intestinal metaplasia (IM) predominantly of incomplete type and no dysplasia.
  • The positivity and distribution of CK7 and CK20 was very similar in the Barrett's mucosa, cardiac mucosa and antral mucosa.

  • Genetic Alliance. consumer health - Gastroesophageal Reflux.
  • MedlinePlus Health Information. consumer health - GERD.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18188921.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


44. Wolfsen HC, Hemminger LL, Achem SR: Eosinophilic esophagitis and Barrett's esophagus with dysplasia. Clin Gastroenterol Hepatol; 2007 Dec;5(12):A18
MedlinePlus Health Information. consumer health - Eosinophilic Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eosinophilic esophagitis and Barrett's esophagus with dysplasia.
  • [MeSH-major] Barrett Esophagus / complications. Eosinophilia / complications. Esophagitis / complications. Intestinal Mucosa / pathology

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Gastroenterol Hepatol. 2008 Jul;6(7):832; author reply 832-3 [18602038.001]
  • (PMID = 18054743.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement